E3, a Willdan Company, Selected for $9.8 Million Technical Services Contract to Support CPUC's Integrated Resource Plan
'We're proud to continue assisting one of the nation's most ambitious clean energy planning initiatives,' said Mike Bieber, Willdan's CEO. 'For over two decades, E3 has provided critical technical expertise and modeling tools to support the CPUC's electricity planning efforts, and we look forward to advancing California's clean energy goals through this continued collaboration.'
About the California Public Utilities Commission
The California Public Utilities Commission is a regulatory agency that regulates privately owned public utilities in the state of California, including electric power, telecommunications, natural gas, and water companies. The CPUC regulates services and utilities, protects consumers, safeguards the environment, and assures Californians access to safe and reliable utility infrastructure and services. Visit www.cpuc.ca.gov for more information.
About Willdan
Willdan is a nationwide provider of professional, technical, and consulting services to utilities, government agencies, and private industry. Willdan's service offerings span a broad set of complementary disciplines that include electric grid solutions, energy efficiency and sustainability, energy policy planning and advisory, engineering and planning, and municipal financial consulting. For additional information, visit Willdan's website at www.willdan.com.
Forward-Looking Statements
Statements in this press release that are not purely historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that Willdan's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the risk factors listed from time to time in Willdan's reports filed with the Securities and Exchange Commission, including, but not limited to, the Annual Report on Form 10-K filed for the year ended December 27, 2024. Willdan cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Willdan disclaims any obligation to, and does not undertake to, update or revise any forward-looking statements in this press release.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
After Trump Warns Elon Musk To 'Close Up Shop,' China Rallies Behind World's Richest Man: 'There's No Need To Keep Putting Up With It'
Tesla Inc. CEO (NASDAQ:TSLA) and the world's richest man, Elon Musk, have found an unusual source of support in the form of Chinese social media users amid the billionaire's ongoing feud with U.S. President Donald Trump over the latter's 'One Big, Beautiful Bill.' What Happened: Users on the Chinese social media platform Weibo have been hailing Musk's stance against Trump with a #MuskWantsToBuildAnAmericaParty going viral on the X (formerly Twitter) counterpart, The Guardian reported on Wednesday. The support comes as Musk had earlier claimed he would found a political party if the Senate passed Trump's Big Beautiful Bill. Trending: GoSun's Breakthrough Rooftop EV Charger Already Has 2,000+ Units Reserved — Several users came out in Musk's support on Weibo. "Brother Musk, you've got over a billion people on our side backing you," one Weibo user wrote. "When you've had enough, there's no need to keep putting up with it," said another user. Some offered deeper insights into what it could mean if Musk were to enter politics. "If Elon Musk were to found a political party, his tech-driven mindset could inject fresh energy into politics. The potential for change is significant – and worth watching," a user It Matters: The news comes as Musk has doubled down on his criticism of the bill, which Musk said increases the U.S. debt ceiling by $5 trillion. He also slammed the politicians backing the bill, saying they would lose their primary "if it is the last thing I do on this Earth," Musk shared. However, Trump called Musk out over his comments. The President said that without subsidies, Musk would have to "have to close up shop and head back home to South Africa" in a post on Truth social. Elsewhere, Tesla's board has received criticism for its silence on the billionaire's comments from experts like Ross Gerber, who says Musk has enabled by endorsing him in the run-up to last year's presidential election. Read Next: Maximize saving for your retirement and cut down on taxes: Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation. These five entrepreneurs are worth $223 billion – they all believe in one platform that offers a 7-9% target yield with monthly dividends Photo Courtesy: Frederic Legrand – COMEO on Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article After Trump Warns Elon Musk To 'Close Up Shop,' China Rallies Behind World's Richest Man: 'There's No Need To Keep Putting Up With It' originally appeared on
Yahoo
an hour ago
- Yahoo
Cantor Fitzgerald Maintains Overweight on Vaxcyte Amid Vaccine Development and ACIP Meeting
Vaxcyte Inc. (NASDAQ:PCVX) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. On June 10, Cantor Fitzgerald reiterated its Overweight rating for Vaxcyte Inc. (NASDAQ:PCVX). The update comes amid speculation regarding the potential effects on pneumococcal vaccine developers following the upcoming meeting of the Advisory Committee on Immunization Practices (ACIP). Cantor Fitzgerald analyst Carter Gould explained the firm's position on Vaxcyte Inc. (NASDAQ:PCVX), pointing out that the upcoming ACIP meeting is unlikely to focus much on pneumococcal disease. This implies that the meeting's talks will have a direct impact on Vaxcyte's operations or prospects. Gould also noted that the potential approval and ACIP recommendation of Vaxcyte's vaccination efforts are still a few years away. The analyst also highlighted the strength of the pneumococcal conjugate vaccine (PCV) data from Vaxcyte Inc. (NASDAQ:PCVX). Gould said that the robustness of this evidence makes a compelling case for sticking with tried-and-true vaccination practices. A clinical-stage vaccine pioneer, Vaxcyte, Inc. (NASDAQ:PCVX) develops, refines, and produces high-fidelity vaccines. The company's medications aim to prevent or cure bacterial illnesses such as Shigella, Group A Strep, invasive pneumococcal disease, and periodontitis. While we acknowledge the potential of PCVX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
an hour ago
- Yahoo
IonQ (NYSE:IONQ) Stock Soars 92% Last Quarter Amid Market Optimism
IonQ recently achieved significant breakthroughs in quantum computing, including the first simulation of neutrinoless double-beta decay and a major milestone in protein folding, which align with the broader trend of rising tech stocks. The company's stock surged by 92% over the last quarter, benefiting from positive market conditions as the S&P 500 and Nasdaq reached all-time highs. In addition, IonQ's alliances with industry leaders like AstraZeneca and AWS to enhance drug development processes may have supported this robust gain, making the company's advancements particularly relevant against a backdrop of tech sector optimism. We've discovered 5 weaknesses for IonQ (1 can't be ignored!) that you should be aware of before investing here. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Over the last three years, IonQ's total shareholder return, including share price appreciation and dividends, experienced a very large increase. This substantial growth far surpassed the US Tech industry's 4.5% decline over the past year, indicating a strong performance relative to the sector. The stock's recent surge aligns with IonQ's advancements in quantum computing and strategic partnerships, as outlined in the introduction, suggesting that these developments may bolster its revenue and earnings forecasts despite current unprofitability. IonQ's stock is trading at a slight discount to consensus analyst price targets as of today, which raises questions about potential market misalignment or anticipation of future growth. While the company's revenue is projected to grow by 40.22% annually, earnings are expected to decline by 2.2% per year over the next three years, indicating ongoing challenges in achieving profitability. The company's strategic initiatives, such as collaborations with AstraZeneca and AWS, may contribute to long-term growth potential, but the market seems cautious given the current valuation. Assess IonQ's previous results with our detailed historical performance reports. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:IONQ. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
